Bacteriophage Therapy of a Vibrio parahaemolyticus Infection Caused by a Multiple-Antibiotic–Resistant O3:K6 Pandemic Clinical Strain

2000, Vibrio parahaemolyticus infections in the United States, 1973–1998, J Infect Dis, 181, 1661, 10.1086/315459

2000, Pandemic spread of an O3:K6 clone of Vibrio parahaemolyticus and emergence of related strains evidenced by arbitrarily primed PCR and toxRS sequence analyses, J Clin Microbiol, 38, 578, 10.1128/JCM.38.2.578-585.2000

2010, Antibiotic susceptibility profiles of some Vibrio strains isolated from wastewater final effluents in a rural community of the Eastern Cape Province of South Africa, BMC Microbiol, 10, 143, 10.1186/1471-2180-10-143

2012, Isolation, molecular characterization, and antibiotic susceptibility of Vibrio parahaemolyticus in Korean seafood, Foodborne Pathog Dis, 9, 224, 10.1089/fpd.2011.1018

2002, Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium, Infect Immun, 70, 204, 10.1128/IAI.70.1.204-210.2002

2005, Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy, Antimicrob Agents Chemother, 49, 2874, 10.1128/AAC.49.7.2874-2878.2005

2008, Therapeutic potential of bacteriophage in treating Klebsiella pneumoniae B5055-mediated lobar pneumonia in mice, J Med Microbiol, 57, 1508, 10.1099/jmm.0.2008/002873-0

2009, Efficacy of bacteriophage treatment in murine burn wound infection induced by Klebsiella pneumoniae, J Microbiol Biotechnol, 19, 622

2005, Bacteriophage therapy in humans, Bacteriophages: biology and applications, 381

2005, Bacteriophage in the treatment of experimental septicemic mice from a clinical isolate of multidrug resistant Klebsiella pneumoniae, J Commun Dis, 37, 18

2010, Isolation and characterization of bacteriophages infecting Staphylococcus epidermidis, Curr Microbiol, 61, 601, 10.1007/s00284-010-9659-5

2012, Complete genome sequence of a novel marine siphovirus, pVp-1, infecting Vibrio parahaemolyticus, J Virol, 86, 7013, 10.1128/JVI.00742-12

2009, Characterization of a T7-like lytic bacteriophage of Klebsiella pneumoniae B5055: a potential therapeutic agent, Curr Microbiol, 59, 274, 10.1007/s00284-009-9430-y

2010, Bacteriophage therapy for Staphylococcus aureus bacteremia in streptozotocin-induced diabetic mice, Res Microbiol, 161, 854, 10.1016/j.resmic.2010.09.011

1999, Using antibodies, a laboratory manual

1998, Bacteriophage diversity in the North Sea, Appl Environ Microbiol, 64, 4128, 10.1128/AEM.64.11.4128-4133.1998

2003, Drug companies snub antibiotics as pipeline threatens to run dry, Nature, 425, 225, 10.1038/425225a

European Society of Clinical Microbiology and Infectious Diseases, 2005, Lack of development of new antimicrobial drugs: a potential serious threat to public health, Lancet Infect Dis, 5, 115, 10.1016/S1473-3099(05)70086-4

2004, The antibiotic pipeline-challenges, costs, and values, N Engl J Med, 351, 523, 10.1056/NEJMp048093

2001, Bacteriophage therapy, Annu Rev Microbiol, 55, 437, 10.1146/annurev.micro.55.1.437

2002, Phage therapy of local and systemic disease caused by Vibrio vulnificus in iron-dextran-treated mice, Infect Immun, 70, 6251, 10.1128/IAI.70.11.6251-6262.2002

1996, Long-circulating bacteriophage as antibacterial agents, Proc Natl Acad Sci U S A, 93, 3188, 10.1073/pnas.93.8.3188

1982, Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics, J Gen Microbiol, 128, 307

2009, Phage therapy, Drug Discov Today, 14, 536, 10.1016/j.drudis.2009.03.006

2004, Preparation of endotoxin-free bacteriophages, Cell Mol Biol Lett, 9, 253

2009, Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials, PLoS One, 4, e4944, 10.1371/journal.pone.0004944

2006, Phage therapy: facts and fiction, Int J Med Microbiol, 296, 5, 10.1016/j.ijmm.2005.09.002

2007, Biotechnological challenges of phage therapy, Biotechnol Lett, 29, 995, 10.1007/s10529-007-9346-1